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Objectives. Our aim was to describe the burden of early dcSSc in terms of disability, fatigue and pain in
the European Scleroderma Observational Study cohort, and to explore associated clinical features.
Methods. Patients completed questionnaires at study entry, 12 and 24 months, including the HAQ dis-
ability index (HAQ-DI), the Cochin Hand Function Scale (CHFS), the Functional Assessment of Chronic
Illness Therapy-fatigue and the Short Form 36 (SF36). Associates examined included the modified Rodnan
skin score (mRSS), current digital ulcers and internal organ involvement. Correlations between 12-month
changes were also examined.
Results. The 326 patients recruited (median disease duration 11.9 months) displayed high levels of dis-
ability [mean (S.D.) HAQ-DI 1.1 (0.83)], with ‘grip’ and ‘activity’ being most affected. Of the 18 activities
assessed in the CHFS, those involving fine finger movements were most affected. High HAQ-DI and CHFS
scores were both associated with high mRSS (r= 0.34, P< 0.0001 and r= 0.35, P< 0.0001, respectively).
HAQ-DI was higher in patients with digital ulcers (P= 0.004), pulmonary fibrosis (P= 0.005), cardiac
(P= 0.005) and muscle involvement (P= 0.002). As anticipated, HAQ-DI, CHFS, the Functional
Assessment of Chronic Illness Therapy and SF36 scores were all highly correlated, in particular the
HAQ-DI with the CHFS (r= 0.84, P<0.0001). Worsening HAQ-DI over 12 months was strongly associated
with increasing mRSS (r= 0.40, P<0.0001), decreasing hand function (r= 0.57, P< 0.0001) and increasing
fatigue (r=0.53, P<0.0001).
Conclusion. The European Scleroderma Observational Study highlights the burden of disability in early
dcSSc, with high levels of disability and fatigue, associating with the degree of skin thickening (mRSS).
Impaired hand function is a major contributor to overall disability.
Key words: early diffuse cutaneous systemic sclerosis, disability, hand function, fatigue, pain
Rheumatology key messages
. Early dcSSc is associated with a high burden of disability, fatigue and pain.
. In early dcSSc, impaired hand function is a major contributor to overall disability.
. Patients with early dcSSc should be referred to a skilled multidisciplinary team.
Introduction
Patients with the diffuse cutaneous subtype of SSc have a
high mortality due to early internal organ involvement of
their disease. It is therefore understandable that in pa-
tients with this subtype of SSc, clinicians have tended to
focus on early recognition and treatment of lung, heart
and kidney involvement. Perhaps less well recognized is
the substantial burden of disability, fatigue and pain of
early dcSSc, caused in large part by progressive skin
tightening and musculoskeletal manifestations: levels of
disability have been found to be higher in patients with
high than with low skin scores [1, 2], and in those with
joint pain, tendon friction rubs and contractures [1].
Thus, early dcSSc can have a major impact on quality of
life.
A Canadian study published in 2011 specifically ad-
dressed the impact of SSc in terms of ability to carry
out everyday activities [3], and highlighted the importance
of fatigue, pain and limitation of hand function. However,
only 59 of the 464 patients studied definitely had the
diffuse cutaneous subtype of SSc (and of unspecified
38Department of Rheumatology, Royal National Hospital for Rheumatic
Diseases, Bath, UK, 39Department of Rheumatology and Clinical
Immunology, Justus-Liebig University Giessen, Kerckhoff Klinik, Bad
Nauheim, Germany, 40Department of Rheumatology, University of
Lu¨beck, Lu¨beck, 41Department of Rheumatology and Clinical
Immunology, University Hospital Charite´ Berlin, Berlin, Germany,
42Department of Rheumatology, Royal Perth Hospital, Perth, Australia,
43Servicio de Reumatologia, Hospital Universitario 12 de Octubre,
Madrid, Spain, 44Internal Medicine Unit, Limoges University Hospital,
Limoges, 45Centre National de Re´fe´rence Maladies Syste´miques et
Auto-immunes Rares, De´partement de Me´decine Interne et
Immunologie Clinique, Universite´ de Lille, Lille, France, 46Department of
Rheumatology, Gateshead Hospitals Foundation Trust, Gateshead, UK,
47Department of Internal Medicine, Division of Rheumatology, Istanbul
Medical Faculty, Istanbul University, Istanbul, Turkey, 48Fife Rheumatic
Diseases Unit, Whyteman’s Brae Hospital, Kirkcaldy, Scotland, UK,
49Department of Rheumatology and Clinical Immunology, UMC Utrecht,
Utrecht, the Netherlands, 50Rheumatology, James Cook University
Hospital, Middlesbrough, UK, 51Rheumatology Unit, Royal Adelaide
Hospital, 52Discipline of Medicine, University of Adelaide, Adelaide,
Australia, 53Department of Rheumatology and Inflammation Research,
The Sahlgrenska Academy at Gothenburg University, Gothenburg,
Sweden, 54Monash Centre for Inflammatory Diseases, Monash
University, Melbourne, Australia, 55Department of Internal Medicine,
Hoˆpital Edouard Herriot, Lyon, 56Department of Internal Medicine,
Foundation Hospital Saint Joseph, Marseille, France, 57Department of
Rheumatology, Cannock Chase Hospital, Cannock, UK,
58Rheumatology, St Vincent’s University Hospital, Dublin, Ireland,
59Department of Internal Medicine 69310, Centre Hospitalier Lyon Sud,
Pierre-Be´nite, Lyon, France, 60Internal Medecine, Ambroise Pare´
Hospital, Boulogne, Billancourt, 61Salford Royal NHS Foundation Trust,
Manchester Academic Health Science Centre, Manchester and 62NIHR
Manchester Musculoskeletal Biomedical Research Unit, Central
Manchester NHS Foundation Trust, Manchester Academic Health
Science Centre, Manchester, UK
Se´bastien Peytrignet et al.
2 https://academic.oup.com/rheumatology
Downloaded from https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/kex410/4675178
by University of Zurich user
on 14 December 2017
duration). Functional impact, fatigue and pain specifically
relating to early diffuse disease have been little studied.
The European Scleroderma Observational Study (ESOS)
[4] was a prospective observational study of treatment
outcome in 326 patients with early dcSSc: data collected
included a number of self-administered questionnaires
relating to functional ability and quality of life. ESOS there-
fore afforded a unique opportunity to perform a detailed
evaluation of disease impact in a large multinational
cohort with very early disease (median disease duration
from onset of skin thickening 11.9 months). Our aim was
to describe, in the ESOS cohort, the burden of early
dcSSc in terms of disability, fatigue and pain and to
explore disease features that associate with this burden
both at the baseline visit and over the subsequent 1224
months. Although some summary data have been
previously reported in the ESOS paper describing
treatment efficacy [4], here we focus (and expand on)
the different measures of disability, fatigue and pain.
Methods
ESOS study design
The study design is described fully elsewhere [4]. In sum-
mary, patients with early dcSSc were recruited into a pro-
spective, observational cohort study (ClinicalTrials.gov
Identifier: NCT02339441), the overall aim of which was
to compare the effectiveness of four different treatment
protocols (MTX, MMF, CYC or no immunosuppressant),
selected on the basis of clinician and patient preference. A
secondary objective of ESOS was to benchmark the se-
verity of disability in patients with early dcSSc, examine
the associates of disability and describe its patterns of
change over the 2-year study period. The main inclusion
criteria for ESOS were early dcSSc (skin involvement ex-
tending to proximal to elbow or knee and/or involving the
trunk [5] and within 3 years of the onset of skin thickening,
to ensure that patients were comparable to those being
included into randomized controlled trials of early disease)
and age >18 years. Patients attended 3-monthly for
1224 months. The primary outcome measure of ESOS
was modified Rodnan skin score (mRSS) [6] and second-
ary outcome measures included questionnaire-based
measures of disability and fatigue as described below.
The Ethics Committee of each participating centre
approved the ESOS study, which this paper was part of,
and each patient gave written informed consent.
Patients
Patient recruitment took place between July 2010 and
September 2014. Demographic and clinical characteris-
tics including age, gender, smoking habit, ethnicity, anti-
body status [anti-topoisomerase-1 (anti-Scl-70), anti-RNA
polymerase III, anticentromere] and presence of visceral
organ involvement were recorded for all patients. Three
hundred and twenty-six patients from 50 centres (in 19
countries) were recruited: 65 started on MTX, 118 on
MMF, 87 on CYC and 56 had no immunosuppressant
[4]. The baseline characteristics of the patients are
described in supplementary Table S1, available at
Rheumatology Online.
Outcome measures relating to functional ability,
fatigue and pain
At the baseline, 12- and 24-month visits, patients were
asked to complete a set of patient questionnaires to
assess functional ability, fatigue and pain. The patient
questionnaires were the Scleroderma Specific HAQ
[sHAQ, including the HAQ disability index (HAQ-DI)], the
Cochin Hand Function Scale (CHFS), the Functional
Assessment of Chronic Illness Therapy (FACIT) fatigue
score and the Short Form 36 Health Survey (SF36), with
brief descriptions and justification for inclusion as follows.
Scleroderma HAQ
Global disability in patients with SSc is usually measured
by the HAQ, a self-report questionnaire consisting of
20 items divided into eight categories (dressing and
grooming, arising, eating, walking, hygiene, reach, grip
and activities), which are averaged into the final HAQ-DI
score [7]. Items are rated from 0 (no difficulty) to 3 (unable
to do). The sHAQ questionnaire [8] includes the generic
HAQ-DI index and six additional disability measures,
graded on a visual analogue scale (VAS) from 0 (least dis-
ability) to 100 (most disability). Using these VAS scales,
patients self-assess the extent to which (in addition to
pain), gastrointestinal symptoms, breathing problems,
RP and digital ulcers interfere with their daily activities,
with an additional scale for perceived overall disease se-
verity from SSc. The HAQ-DI is a validated outcome
measure for use in clinical studies in patients with SSc
as per OMERACT criteria [9]. The HAQ-DI and sHAQ
have both been widely applied in studies of SSc [10].
Cochin (Duruo¨z) Hand Function Scale
The CHFS (Duruo¨z) [11] index corresponds to the sum of
18 questions relating to the difficulty of daily manual activ-
ities at the time of assessment. Each individual question is
ranked on a Likert scale from 0 (without difficulty) to 5
(impossible to do). The total score is obtained by adding
the scores of all items (range 090). The reliability and
validity of the CHFS have been demonstrated in patients
with SSc [12, 13]. Because of translational issues, patients
from certain centres did not complete the CHFS.
FACIT fatigue scale
The FACIT fatigue index is derived from a 13-item ques-
tionnaire, measuring the extent of a patient’s fatigue over
the past week [14]. The final FACIT fatigue score is graded
from 0 (higher fatigue) to 52 (lower fatigue).
SF36
The Medical Outcome Study 36-item SF36 questionnaire is
a generic measure of health-related quality of life in relation
to the previous 4 weeks. This self-administered question-
naire covers eight areas: physical function, physical role,
bodily pain, general health, vitality, social function, emotional
role and mental health. For each area, the score ranges from
0 (poorer health status) to 100 (better health status). Scores
Associates of disability in early diffuse SSc
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can also be summarized in two global scores: the physical
(PCS) and mental (MCS) component summaries [15].
Statistical analysis
In analysing baseline and follow-up data, the immunosup-
pressant treatment assignment was not accounted for,
given that the goal of this paper was not to establish a
causal effect between any of these treatments and the
progression of disability.
Baseline associations of disability
In order to assess baseline associations between patient
characteristics and levels of disability, the distribution of
each disability indicator was compared between levels of
categorical variables (e.g. gender or presence of organ
involvement) using the KruskalWallis test. For continuous
variables, Spearman’s correlation (r) was used to examine
associations with the disability indicators. Each pair of
continuous variables uses the subset of observations
available to compute each r. Unadjusted P-values are
reported, with an additional significance level supplied in
Table 1 corresponding to the Sˇida´k correction for multiple
testing.
Changes in disability
Patterns of change were examined by computing the
shares of improvers and regressors (of any magnitude)
for each indicator during the first 12 months.
Associates of changes in disability
Spearman’s correlation (r) was used to examine associ-
ations between the 12-month evolution of each disability
indicator with the evolution in corresponding continuous
variables. For instance, we evaluated the association be-
tween the increase in skin fibrosis (mRSS) and the change
in disability. The numbers of observations for each pair of
variables differ due to data availability and loss to follow-
up. Simple linear regression was used to translate these
correlations into marginal effects due to changes.
Results
Baseline values
Baseline distribution of HAQ-DI
The mean (S.D.) and median (interquartile range, IQR)
HAQ-DI scores were 1.1 (0.83) and 1.0 (0.41.8), respect-
ively (Fig. 1 and Table 1). Fifty (16.3%) patients reported a
HAQ-DI lower than 0.15, including 36 null scores, indicat-
ing no or very low disability for these patients. On the
other hand, 10 (3.3%) patients reported a score of 2.75
or higher, indicating severe disability.
By subdividing the HAQ-DI index into its eight compo-
nents, grip and activity contributed the most, with 49.0%
and 39.0% of patients being ‘unable’ or reporting much
difficulty in the corresponding questions (Fig. 2). Rising
and walking were the items that contributed the least to
disability with minimal impact on the total HAQ-DI score
(78.0 and 75.8% were able to perform these tasks without
any or only some difficulty).
Baseline distribution of CHFS
Out of 230 patients with a CHFS score at baseline, the
mean (S.D.) and median (IQR) CHFS were 18.7 (20.7) and
11 (3.029.0), respectively (Fig. 1 and Table 1), while 28
(12.2%) patients reported no impairment in hand function
according to the CHFS.
Out of 18 activities assessed by the hand function ques-
tionnaire, picking up coins, peeling fruit and buttoning a
shirt (i.e. activities involving fine finger movements) had
the highest mean difficulty (Fig. 2). On the other hand,
squeezing a new tube of toothpaste, pricking things with
a fork and holding a bowl (activities requiring less dexter-
ity) had the lowest mean difficulty.
Baseline distribution of FACIT fatigue
The mean (S.D.) and median (IQR) scores were 30.2 (13.0)
and 31.0 (20.041.0), respectively (Fig. 1 and Table 1).
Among the questionnaire items, 110 patients (35.8%) re-
ported feeling quite a bit or very much fatigued. By the
same approach, 120 (38.7%) patients reported frustration
from being too tired to do the things they want to do and
23 (7.4%) reported being too tired to eat (Fig. 2).
Other measures
The mean (S.D.) and median (IQR) scores for the SF36
physical component (PCS) were 36.9 (9.7) and 37.4
(29.945.0), respectively, and were 38.5 (7.1) and 38.3
(34.344.0) for the mental component (MCS). For the
sHAQ pain scale, the mean (S.D.) and median (IQR)
scores were 32.9/100 (26.9) and 29.0/100 (8.752.7)
(Fig. 1 and Table 1).
Baseline associations
HAQ-DI [03 (3 most disabled)]
Table 1 and Fig. 3 indicate that many clinical and labora-
tory features of dcSSc were associated with increased
disability: current or previous steroid use (P= 0.002), cur-
rent digital ulcers (P= 0.004, with a difference in medians
of 0.6 unit between those with and without ulcers), pul-
monary fibrosis [P= 0.005, and with reduced forced vital
capacity (FVC; P= 0.001) and carbon monoxide diffusing
capacity (DLCO; P= 0.001)], cardiac involvement
(P= 0.005) and muscle involvement (P= 0.002). Disability
was not correlated with the duration of skin thickening,
although there was a correlation with total skin thickening
(r= 0.34, P< 0.0001) as well as with skin thickening as
measured in the fingers and dorsum of hand (r= 0.23,
P< 0.0001). Lower levels of haemoglobin and higher
levels of platelets, ESR and CRP associated with higher
HAQ-DI scores (P< 0.0005 for all four). As expected, the
HAQ-DI score was strongly associated with the other dis-
ability indexes and in particular the CHFS (r= 0.84,
P< 0.0001) (Fig. 3).
CHFS hand function [090 (90 most disabled)]
The following were associated with reduced hand func-
tion: current or previous corticosteroid use (P= 0.009),
current digital ulcers (P= 0.025 and 8.5 difference
in median CHFS scores) and pulmonary fibrosis
Associates of disability in early diffuse SSc
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[P= 0.019, and with reduced FVC (P= 0.016) and DLCO
(P= 0.008)] (Table 1 and Fig. 4). Skin thickening was
also correlated with impaired hand function (r= 0.35,
P< 0.0001) although its duration was not (P= 0.901).
Among other disability indicators, pain and the
severity of RP (from the sHAQ questionnaire) were
both strongly associated with impaired hand function
(r= 0.59 for pain and r= 0.43 for Raynaud’s, P< 0.0001
for both).
FACIT fatigue [052 (0 most disabled)]
Associated with increased fatigue were current or previ-
ous use of corticosteroids (P= 0.004) and several indica-
tors of organ involvement: pulmonary fibrosis [P< 0.0005,
and with reduced FVC (P< 0.0001) and DLCO
(P< 0.0005)] and pulmonary hypertension (P= 0.006),
and renal and cardiac involvement (P= 0.013 and
P= 0.001, respectively) (Table 1). Skin thickening was
also associated with more fatigue (r=0.20,
P= 0.0005). Lower levels of haemoglobin (P< 0.0001)
and higher levels of CRP (P< 0.001) and ESR
(P< 0.0005) were associated with more fatigue.
SF36 physical and mental components [0100
(0 most disabled)]
As shown in Table 1, associations of lower SF36 physical
component (PCS) scores (representing increased physical
disability) included current or previous use of corticosteroids
(P=0.004), pulmonary fibrosis [P=0.004, and with reduced
FVC (P< 0.0005) and DLCO (P< 0.0001)], cardiac (P=0.007)
and muscle involvement (P=0.009), and increased skin
thickening (P< 0.0001). The mental component (SF36
MCS) was not significantly associated with organ involve-
ment measures and was not significantly correlated with
the extent of skin thickening. The strongest association of
the SF36 MCS score was with fatigue (r=0.29, P< 0.0001).
sHAQ Pain VAS scale [0100 (100 most disabled)]
Patients with pulmonary fibrosis (P= 0.033) and cardiac
involvement (P= 0.088) reported more pain compared
with those without (Table 1). Older patients tended to
report slightly lower levels of pain (r=0.11, P= 0.055).
Skin thickening was associated with more pain (r= 0.17,
P= 0.002), as were higher levels of ESR and CRP
(P= 0.015 and P= 0.002, respectively). Pain correlated
FIG. 1 Baseline distribution of disability indicators
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CHFS: Cochin Hand Function Scale; FACIT: Functional Assessment of Chronic Illness Therapy; HAQ-DI: HAQ disability
index; MCS: mental component summary; PCS: physical component summary; SF36: Short Form 36 Health Survey;
sHAQ: Scleroderma HAQ.
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FIG. 2 Composition of disability indicators at baseline
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individual question. CHFS: Cochin Hand Function Scale; FACIT: Functional Assessment of Chronic Illness Therapy;
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strongly with other disability measures, including HAQ-DI,
hand function and fatigue (P< 0.0001 for all three).
Changes in disability
Trajectories of disability
The 12-month changes in all indicators followed an ap-
proximately normal distribution centred around zero and
underline the heterogeneity in the evolution of disability
(supplementary Fig. S1, available at Rheumatology
Online). For the HAQ-DI, changes ranged from 1.95 to
1.67 in the first 12 months. There was a tendency, for each
measure of disability, for half of the cohort to improve
while the other became more disabled.
Supplementary Fig. S2 available at Rheumatology
Online plots the baseline values of the HAQ-DI, CHFS,
FACIT fatigue, SF36 (physical and mental components)
and sHAQ Pain VAS against their change in the
12 months. In general, those with more disability at base-
line tended to improve while those with the least disability
tended to become worse (suggesting regression to
the mean). Supplementary Fig. S3, available at
Rheumatology Online, describes the evolution of these
indicators from baseline to 24 months, further underlining
the variability in individual trajectories.
Associates of changing disability
The data on 12-month changes are shown in supplemen-
tary Table S2, available at Rheumatology Online, with
changes in several of the measures of disability correlating
with each other. Worsening disability according to HAQ-DI
was strongly associated with increasing overall skin
thickening (r= 0.40, P< 0.0001), decreasing hand func-
tion (r= 0.57, P< 0.0001) and increasing fatigue
(r=0.53, P< 0.0001). In addition, worsening hand func-
tion was also associated with increasing fatigue
(r=0.50, P< 0.0001). In a regression setting, a 5 unit
increase in the skin score resulted in a 0.15 unit increase
in the HAQ-DI (03) and a 1.58 increase in the CHFS index
(090) (Fig. 5).
FIG. 3 Associates of HAQ disability index
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For the relation between HAQ-DI and binary variables (here current digital ulcers and pulmonary fibrosis), box plots
(with median and interquartile ranges) summarize the distribution of the index within each level of the binary variable.
In addition, a strip plot shown next to each box plot gives more detail on the dispersion of all individual points. For the
relation between HAQ-DI and continuous variables (here mRSS, CHFS and sHAQ Pain VAS), a scatter plot is shown
for each pair and superimposed with a linear regression line to describe the correlation direction. CHFS: Cochin Hand
Function Scale; mRSS: modified Rodnan skin score; sHAQ: Scleroderma HAQ.
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Discussion
ESOS has benchmarked the high burden of disability, fa-
tigue and pain in patients with early dcSSc. Although sev-
eral recent studies (as discussed below) have reported the
functional disability, fatigue and pain associated with SSc,
ESOS is the first to make such a detailed analysis specif-
ically in patients with the early dcSSc subtype, and has
provided new insights into the associates of disability and
fatigue in this patient population. Disability, fatigue and
pain were all associated with mRSS (the greater the
degree of skin thickening, the greater the disability, fatigue
and pain), with hand function, and with internal organ in-
volvement. In addition, HAQ-DI and hand function were
reduced in patients with current digital ulcers, reinforcing
previous reports of the functional impact of SSc-related
digital ulcers [1620].
Patients with the early diffuse cutaneous subtype of
SSc have a particular set of problems, with rapidly pro-
gressive skin thickening (often with early contractures)
and internal organ involvement. We have shown that this
skin thickening is likely to be a key driver of disability, in
large part through its effect on hand function: not only
were HAQ-DI and CHFS associated with mRSS (reflecting
the extent of skin thickening) at baseline, but changes in
HAQ-DI over 12 months correlated with changes in mRSS
(including specifically with changes in skin score relating
to the hands). This suggests the changes are not gener-
ated simply by regression to the mean, and makes clinical
sense: stiff, painful, hands (due to skin thickening) impact
significantly on an individual’s ability to perform activities
of everyday living, and this is further exacerbated if there
is concomitant finger ulceration.
The association between both disability and fatigue with
internal organ involvement is also of interest. Here inter-
relationships are likely to be more complex. In part,
internal organ involvement will be an index of disease se-
verity (associating with extent of skin thickening [4, 21]),
but some internal organ involvements, for example
pulmonary fibrosis and muscle involvement, are in them-
selves fatiguing.
FIG. 4 Associates of Cochin hand function scale
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For the relation between CHFS and binary variables (here current digital ulcers and pulmonary fibrosis), box plots
(with median and interquartile ranges) summarize the distribution of the index within each level of the binary variable.
In addition, a strip plot shown next to each box plot gives more detail on the dispersion of all individual points. For the
relation between CHFS and continuous variables (here mRSS and sHAQ Pain VAS), a scatter plot is shown for each pair
and superimposed with a linear regression line to describe the correlation direction. CHFS: Cochin Hand Function Scale;
mRSS: modified Rodnan skin score; sHAQ: Scleroderma HAQ.
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Steen and Medsger [8] reported a mean HAQ-DI of 1.22
in 222 patients with early dcSSc (<3 years’ duration), and
0.72 in patients with (any duration of) lcSSc. This value of
1.22 is comparable to that in the ESOS cohort (1.1), and
indicates a high level of disability. Steen and Medsger also
reported that among the 163 patients with contemporan-
eous HAQ-DI and skin score data, increasing and
decreasing skin scores were associated (respectively)
with an increase and decrease in HAQ-DI, with changes
in skin score correlating with changes in HAQ-DI (as we
have also found). Although it is unclear how many of these
163 patients had diffuse cutaneous disease, 55% of the
whole cohort had dcSSc [8]. The HAQ-DI score of 1.1 also
closely matches scores in a meta-analysis of clinical trials
in dcSSc including 629 patients [22]. High HAQ-DI scores
have, unsurprisingly, been associated with work disability
in patients with SSc [23], just one reflection of how func-
tional disability impacts on patients’ lives in many different
ways.
Previous studies have reported that hand function is
more compromised in patients with dcSSc than lcSSc
[12, 13], but these were not studies conducted specifically
in patients with early disease. In the ESOS cohort, the
degree of hand impairment correlated with skin score,
and activities involving fine finger movement were espe-
cially affected. Although Brower and Poole [12] did not
report a significant correlation between CHFS and skin
score, most patients in this study had established limited
cutaneous disease (mean duration 11 years) and therefore
it is possible that other factors often associated with dis-
ease duration, for example severity of digital vasculopathy
and degree of contracture, could have been more influen-
tial than skin tightening in impairing hand function (as was
found by Mouthon et al. [16]). Our finding suggests that in
early dcSSc, skin thickening in itself is a major contributor
to hand disability, and that impaired hand function is a
major contributor to overall disability, confirming the re-
sults obtained by Rannou et al. [13] who identified that
hand disability explained 75% of the variance of global
disability in a cohort of patients with either lcSSc or
dcSSc. In that study [13], a significant difference was
observed between patients with lcSSc and dSSc for
mean CHFS score [11.07 ± 11.04 vs 23.48 ± 19.45, re-
spectively (P= 0.01)]. In the ESOS cohort, the median
CHFS was 11, which is lower than in other studies, a
finding possibly explained by the early disease: Brower
and Poole [12] reported a mean score of 21.1 in their
cohort of 40 patients with a mean disease duration of
FIG. 5 Co-movements of skin score and disability indicators in first 12 months
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These four scatter plots describe the 12 month changes in mRSS (overall and in fingers and hand dorsum) with respect
to the change in HAQ-DI and CHFS. In each axis, the symbol  denotes change. A regression line shows in each case
the marginal effect of a 1 unit increase in the skin score, equal to the regression coefficient (b), shown here alongside its
significance P-value. CHFS: Cochin Hand Function Scale; HAQ-DI: HAQ disability index; mRSS: modified Rodnan skin
score.
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11 years [12], whereas Mouthon et al. [16] reported a
mean score of 20.15 in a cohort of 213 patients with a
mean disease duration of 10.4 years.
Fatigue is now recognized as a very major symptom in
most patients with SSc with a number of recent studies
describing fatigue and its associates [3, 2428], previously
reported associates of fatigue including pain and poor
physical function [25], symptoms suggestive of internal
organ involvement (breathing problems and gastrointes-
tinal symptoms [26]) and ability to work [27]. Again, the
contribution of ESOS has been to quantify fatigue and
describe the associates of fatigue specifically in early
dcSSc: these associates include extent of skin thickening
and internal organ involvement. SF36 MCS scores were
lower than in some other studies of SSc [13, 29], indicat-
ing more disability, perhaps due to all patients in ESOS
having early diffuse cutaneous disease.
Pain, as measured by VAS, was also associated with
degree of skin thickening. We found that pain was also
associated with all measures of disability, confirming re-
sults from a previous study of 89 patients (67 had dcSSc)
in whom pain was correlated with both physical and
mental components of the SF36 [30], and from a very
recent study from the Canadian Scleroderma Research
Group [31]. However, the majority of patients in the
latter study had limited cutaneous disease [31]. The pain
associated with the skin thickening of early dcSSc has in
the past been insufficiently recognized.
In conclusion, the message of our analysis is straight-
forward—early dcSSc is disabling, fatiguing and asso-
ciated with severe compromise in hand function and
with pain. As options for treating the life-threatening
organ-based complications improve, the non-lethal
burden is likely to require increasing attention for therapy.
Pending the development of effective treatments to pre-
vent or reverse progression of this devastating disease,
clinicians need to be aware of this huge burden of disabil-
ity, and recognize each patient’s need for multidisciplinary
input including physiotherapy [32], occupational therapy
and pain management, to minimize the impact on the
individual. Ideally all patients with early dcSSc should be
referred at the earliest opportunity to a skilled multidiscip-
linary team.
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